Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
| End Date: | February 2012 |
A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage)for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Renal cell carcinoma patients' blood will be monitored over a period of 15 weeks to evaluate
their level of immune response to multiple administration of HSPPC-96.
A multicenter, randomized, single-blind study to assess patients' immune response following
treatment with HSPPC-96 (vitespen, Oncophage®)for resectable renal cell carcinoma (RCC),
considered to be at intermediate risk for recurrence given the pathologic tumor stage at
time of resection.
The purpose of this study is to determine whether patients exhibit a measurable and durable
immune response after multiple administrations of HSPPC-96 during a maximum 15-month time
period.
The study consists of two parts: Part 1 with Part 1a (Assessment of Immune Variation)and
Part 1b (Assay Standardization), and Part 2 (Immune Monitoring Study).
We found this trial at
2
sites
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
Click here to add this to my saved trials